Baxter

Baxter, a US-headquartered company in Surgical and Medical Instrument Manufacturing, is actively working to reduce its carbon footprint and has made several climate commitments.

For the most recent reporting year, 2024, Baxter's total greenhouse gas emissions were approximately 4.33 billion kg CO2e. This comprised:

• Scope 1 emissions: approximately 324 million kg CO2e
• Scope 2 emissions (market-based): approximately 177 million kg CO2e
• Scope 3 emissions: approximately 3.83 billion kg CO2e

Looking back, Baxter's total emissions in previous years were:

• 2023: approximately 4.06 billion kg CO2e
• 2022: approximately 4.42 billion kg CO2e
• 2021: approximately 3.80 billion kg CO2e
• 2020: approximately 6.11 billion kg CO2e

Baxter has set ambitious climate targets, including a commitment to achieve carbon neutrality for its direct operations (Scope 1 and 2 GHG emissions) by 2040. Furthermore, the company aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline, which aligns with a well-below 2° Celsius science-based target. Baxter also has a long-term goal for Net-Zero greenhouse gas emissions across Scope 1 and Scope 2 by 2050.

Historically, Baxter has demonstrated efforts in emissions reduction, having extended a commitment to reduce GHG emissions from operations by 45% indexed to revenue by 2015, compared to a 2005 baseline. The company reported exceeding its 2010 target of a 20% reduction indexed to revenue, achieving a 7% absolute reduction and a 29% reduction indexed to revenue from 2005 to 2010. Since 2007, Baxter has also maintained carbon neutrality at its headquarters in Deerfield, Illinois, US, and its manufacturing facility in Cartago, Costa Rica, through renewable energy, carbon credits, and offsets.